AKTS
Price:
$19.92
Market Cap:
$1.05B
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD...[Read more]
Industry
Biotechnology
IPO Date
2026-01-09
Stock Exchange
NASDAQ
Ticker
AKTS
According to Aktis Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is 65.59%. This represents a change of 1.33% compared to the average of 4.58% of the last 4 quarters.
The mean historical ROE of Aktis Oncology, Inc. over the last ten years is 68.39%. The current 65.59% ROE has changed -4.10% with respect to the historical average. Over the past ten years (40 quarters), AKTS's ROE was at its highest in in the December 2024 quarter at 13.73%. The ROE was at its lowest in in the September 2024 quarter at 0%.
Average
68.39%
Median
61.85%
Minimum
50.09%
Maximum
93.23%
Discovering the peaks and valleys of Aktis Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 93.23%
Minimum Annual Increase = -33.66%
Minimum Annual ROE = 50.09%
| Year | ROE | Change |
|---|---|---|
| 2024 | 50.09% | -19.02% |
| 2023 | 61.85% | -33.66% |
The current ROE of Aktis Oncology, Inc. (AKTS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
68.39%
5-year avg
68.39%
10-year avg
68.39%
Aktis Oncology, Inc.’s ROE is
| Company | ROE | Market cap |
|---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aktis Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aktis Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aktis Oncology, Inc.'s ROE?
How is the ROE calculated for Aktis Oncology, Inc. (AKTS)?
What is the highest ROE for Aktis Oncology, Inc. (AKTS)?
What is the 3-year average ROE for Aktis Oncology, Inc. (AKTS)?
What is the 5-year average ROE for Aktis Oncology, Inc. (AKTS)?
How does the current ROE for Aktis Oncology, Inc. (AKTS) compare to its historical average?